GLPwatch
Rybelsus for Bipolar disorder
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCRybelsus (semaglutide) is not FDA-approved for bipolar disorder, and any use for this condition is off-label or investigational. The listed research examines psychiatric adverse events, weight management in patients with antipsychotic-induced weight gain, and potential interactions with lithium but does not establish efficacy for treating bipolar disorder.
AI summary of the sources below.
| Drug | Rybelsus (semaglutide) |
|---|---|
| Condition | Bipolar disorder |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Rybelsus is not FDA-approved for bipolar disorder; the research below reflects investigational or off-label study only.
Research on semaglutide for bipolar disorder (7)
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.
- Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.